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ABSTRACT 
 
For pain research, the orofacial region is unique in a number of ways. The region has 
complex local anatomy, including substantial sensory innervation from neural pathways, and 
muscles of facial expression that convey important information concerning pain intensity and 
associated psychological traits. Although chronic orofacial pain conditions appear 
prevalent, useful documentation on pain intensity ratings using well established instruments 
is sparse. In particular, two conditions, atypical facial pain and atypical odontalgia, are 
poorly understood in aetiology so that definitive treatment modalities are severely limited. 
The region’s local biofluid, saliva, has been used to diagnose various local and systemic 
disease states, and to quantitate drug concentrations. However, recent studies indicate that 
saliva also contains some of the same peptides, e.g. bradykinin, that are involved in pain 
mechanisms. It may be that pharmacological-pharmacokinetic studies of these peptides 
could shed more information on the significance of their presence in saliva.  
 
This thesis consists of four major sections. Section 1 comprises of three clinical studies 
investigating orofacial pain. Section 2 deals with clinical laboratory studies of saliva. Section 
3 is concerned with the development of chromatographic methods to assay bradykinin and 
its pharmacokinetics in saliva. Section 4 uses chromatography for the identification of novel 
salivary peptides. This thesis, then, presents clinical studies of orofacial pain and 
pharmacological investigations of saliva as the local biofluid. 
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Section 1 
Study 1 analysed 120 consecutive patients with chronic orofacial pain who completed a 
comprehensive questionnaire that included pain intensity scales (McGill Pain Questionnaire 
and visual analogue scale). The most frequent condition diagnosed was atypical facial pain 
(n = 40), followed by temporomandibular disorder (n = 32), atypical odontalgia (n = 29) 
and pain arising from recognised pathology of the orofacial region (n = 19). Results 
showed a disproportionate female : male ratio (88 : 32) (P < 0.001) in the study group, 
and in the subgroup of patients diagnosed with atypical facial pain (34 : 6) (P < 0.001). 
Temporomandibular disorder was present in 65% subjects as the sole pain complaint (n = 
32) or as a secondary condition (n = 43). The Pain Rating Index (Total) of chronic 
orofacial pain conditions was similar to other chronic pain conditions including back pain, 
cancer pain and arthritis. Patients diagnosed with multiple orofacial pain complaints 
reported higher Pain Rating Index (Miscellaneous and Total) scores than those patients 
with a single diagnosis. A significant positive relationship was found between visual 
analogue scores and the Number of Words Chosen rating (P = 0.002). 
 
Study 2 examined patients with a diagnosis of atypical facial pain. The current IASP 
definition interprets this condition as “psychogenic pain” and specifically excludes an 
organic basis or component. Results of this study revealed that these patients  described 
pain with sensory qualities, which is highly suggestive of underlying, but undetected, 
pathophysiology. Furthermore, a majority of patients were diagnosed with an associated 
temporomandibular disorder. It is proposed that patients with atypical facial pain have an 
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organic component contributing to pain, but psychological factors can magnify the affective 
component of ‘pain and suffering’ on clinical presentation.  
 
Study 3 evaluated 50 patients diagnosed with atypical odontalgia. Patients underwent 
pharmacological tests including topical anaesthetic application and phentolamine infusion. 
Therapeutic trials of topical capsaicin were carried out to assess its efficacy for pain 
reduction. Results showed that 34 females and 16 males, with an age range of 21 - 82 
years, were diagnosed with the condition. Dental treatment triggered the pain in 74% of 
patients. The pain was generally “constant” (80% of patients) and “medium” to “severe” in 
intensity (78%). A secondary temporomandibular disorder was present in 35 patients. 
EMLA topical anaesthetic cream applied to the site of intraoral pain for five minutes caused 
a significant reduction in pain intensity as measured by the visual analogue scale (P < 
0.0001). Patient-blinded saline / phentolamine infusions demonstrated that there was a 
variable contribution to the pain condition from the sympathetic nervous system. A four 
week trial of topical capsaicin resulted in 19 / 30 patients reporting a significant pain 
reduction (P < 0.0001), which was maintained at long term review in the majority of 
patients. The response to these pharmacological procedures and the high occurrence of 
dental treatment in the aetiology of atypical odontalgia is highly suggestive that this condition 
is a neuropathic pain of the oral cavity. 
 
Section 2  
Study 4 assessed whether measurements of concentrations of salivary bradykinin might be 
useful markers in quantifying pain states. This was a screening study based on preliminary 
 VI
chromatographic ‘fingerprint’ profiles obtained from patients with pain. The preliminary 
work assaying saliva showed that chromatographic profiles of patients with different pain 
conditions were markedly different compared to patients without pain; further development 
may result in a ‘fingerprint’ of different pain states. Study 5 investigated bradykinin as a 
possible marker in these profiles. The results assessing salivary bradykinin concentrations 
showed that there was wide intersubject variation among healthy controls and several 
groups of patients with pain (cancer pain, arthritis and post-operative pain). Generally, 
females and surgical post-operative patients were found to have quantifiable levels of 
salivary bradykinin. 
 
Section 3 
Based on the results of study 5, the pharmacokinetics of salivary bradykinin were 
investigated. For this study, an alternative bradykinin assay to immunoassay was developed 
using high-performance liquid chromatography. The purpose of using chromatography is 
that other peptides potentially involved in pain pathways could be investigated with relative 
ease using identical or similar (i.e. minor changes in mobile phase chemistry) 
chromatographic conditions. A chromatographic assay for salivary bradykinin was 
successfully developed that is rapid and simple in sample preparation and mobile phase 
chemistry. Study 6 assessed the degradation and stability of salivary bradykinin. Metabolic 
clearance of bradykinin using an ex vivo model showed that its clearance was much slower 
than its known plasma pharmacokinetics. The method required stabilisation of salivary 
bradykinin that was achieved at low pH; saliva at pH 2 through the addition of 
orthophosphoric acid showed excellent stability for five to nine days at 200C and for 60 
 VII
days at 40C.   Study 7 determined the salivary bradykinin concentrations in healthy subjects 
and it  showed this peptide to be present in concentrations at several orders of magnitude 
greater than reported plasma concentrations. 
 
Section 4 
Chromatographic assays were optimised to identify a variety of novel salivary peptides. In 
conjunction with mass spectrometry, novel salivary peptides defensin HNP-1 and HNP-2 
have been identified. These peptides have proven antimicrobial, antifungal and antiviral 
(including anti-HIV) activities. There were high concentrations of these salivary defensin 
peptides (2-350 mg/mL) in ten healthy subjects; this may have potentially important 
therapeutic applications such as the prevention and / or treatment of oral candidiasis and 
other infections. 
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ABSTRACT 
 
For pain research, the orofacial region is unique in a number of ways. The region has 
complex local anatomy, including substantial sensory innervation from neural pathways, and 
muscles of facial expression that convey important information concerning pain intensity and 
associated psychological traits. Although chronic orofacial pain conditions appear 
prevalent, useful documentation on pain intensity ratings using well established instruments 
is sparse. In particular, two conditions, atypical facial pain and atypical odontalgia, are 
poorly understood in aetiology so that definitive treatment modalities are severely limited. 
The region’s local biofluid, saliva, has been used to diagnose various local and systemic 
disease states, and to quantitate drug concentrations. However, recent studies indicate that 
saliva also contains some of the same peptides, e.g. bradykinin, that are involved in pain 
mechanisms. It may be that pharmacological-pharmacokinetic studies of these peptides 
could shed more information on the significance of their presence in saliva.  
 
This thesis consists of four major sections. Section 1 comprises of three clinical studies 
investigating orofacial pain. Section 2 deals with clinical laboratory studies of saliva. Section 
3 is concerned with the development of chromatographic methods to assay bradykinin and 
its pharmacokinetics in saliva. Section 4 uses chromatography for the identification of novel 
salivary peptides. This thesis, then, presents clinical studies of orofacial pain and 
pharmacological investigations of saliva as the local biofluid. 
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Section 1 
Study 1 analysed 120 consecutive patients with chronic orofacial pain who completed a 
comprehensive questionnaire that included pain intensity scales (McGill Pain Questionnaire 
and visual analogue scale). The most frequent condition diagnosed was atypical facial pain 
(n = 40), followed by temporomandibular disorder (n = 32), atypical odontalgia (n = 29) 
and pain arising from recognised pathology of the orofacial region (n = 19). Results 
showed a disproportionate female : male ratio (88 : 32) (P < 0.001) in the study group, 
and in the subgroup of patients diagnosed with atypical facial pain (34 : 6) (P < 0.001). 
Temporomandibular disorder was present in 65% subjects as the sole pain complaint (n = 
32) or as a secondary condition (n = 43). The Pain Rating Index (Total) of chronic 
orofacial pain conditions was similar to other chronic pain conditions including back pain, 
cancer pain and arthritis. Patients diagnosed with multiple orofacial pain complaints 
reported higher Pain Rating Index (Miscellaneous and Total) scores than those patients 
with a single diagnosis. A significant positive relationship was found between visual 
analogue scores and the Number of Words Chosen rating (P = 0.002). 
 
Study 2 examined patients with a diagnosis of atypical facial pain. The current IASP 
definition interprets this condition as “psychogenic pain” and specifically excludes an 
organic basis or component. Results of this study revealed that these patients  described 
pain with sensory qualities, which is highly suggestive of underlying, but undetected, 
pathophysiology. Furthermore, a majority of patients were diagnosed with an associated 
temporomandibular disorder. It is proposed that patients with atypical facial pain have an 
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organic component contributing to pain, but psychological factors can magnify the affective 
component of ‘pain and suffering’ on clinical presentation.  
 
Study 3 evaluated 50 patients diagnosed with atypical odontalgia. Patients underwent 
pharmacological tests including topical anaesthetic application and phentolamine infusion. 
Therapeutic trials of topical capsaicin were carried out to assess its efficacy for pain 
reduction. Results showed that 34 females and 16 males, with an age range of 21 - 82 
years, were diagnosed with the condition. Dental treatment triggered the pain in 74% of 
patients. The pain was generally “constant” (80% of patients) and “medium” to “severe” in 
intensity (78%). A secondary temporomandibular disorder was present in 35 patients. 
EMLA topical anaesthetic cream applied to the site of intraoral pain for five minutes caused 
a significant reduction in pain intensity as measured by the visual analogue scale (P < 
0.0001). Patient-blinded saline / phentolamine infusions demonstrated that there was a 
variable contribution to the pain condition from the sympathetic nervous system. A four 
week trial of topical capsaicin resulted in 19 / 30 patients reporting a significant pain 
reduction (P < 0.0001), which was maintained at long term review in the majority of 
patients. The response to these pharmacological procedures and the high occurrence of 
dental treatment in the aetiology of atypical odontalgia is highly suggestive that this condition 
is a neuropathic pain of the oral cavity. 
 
Section 2  
Study 4 assessed whether measurements of concentrations of salivary bradykinin might be 
useful markers in quantifying pain states. This was a screening study based on preliminary 
 VI
chromatographic ‘fingerprint’ profiles obtained from patients with pain. The preliminary 
work assaying saliva showed that chromatographic profiles of patients with different pain 
conditions were markedly different compared to patients without pain; further development 
may result in a ‘fingerprint’ of different pain states. Study 5 investigated bradykinin as a 
possible marker in these profiles. The results assessing salivary bradykinin concentrations 
showed that there was wide intersubject variation among healthy controls and several 
groups of patients with pain (cancer pain, arthritis and post-operative pain). Generally, 
females and surgical post-operative patients were found to have quantifiable levels of 
salivary bradykinin. 
 
Section 3 
Based on the results of study 5, the pharmacokinetics of salivary bradykinin were 
investigated. For this study, an alternative bradykinin assay to immunoassay was developed 
using high-performance liquid chromatography. The purpose of using chromatography is 
that other peptides potentially involved in pain pathways could be investigated with relative 
ease using identical or similar (i.e. minor changes in mobile phase chemistry) 
chromatographic conditions. A chromatographic assay for salivary bradykinin was 
successfully developed that is rapid and simple in sample preparation and mobile phase 
chemistry. Study 6 assessed the degradation and stability of salivary bradykinin. Metabolic 
clearance of bradykinin using an ex vivo model showed that its clearance was much slower 
than its known plasma pharmacokinetics. The method required stabilisation of salivary 
bradykinin that was achieved at low pH; saliva at pH 2 through the addition of 
orthophosphoric acid showed excellent stability for five to nine days at 200C and for 60 
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days at 40C.   Study 7 determined the salivary bradykinin concentrations in healthy subjects 
and it  showed this peptide to be present in concentrations at several orders of magnitude 
greater than reported plasma concentrations. 
 
Section 4 
Chromatographic assays were optimised to identify a variety of novel salivary peptides. In 
conjunction with mass spectrometry, novel salivary peptides defensin HNP-1 and HNP-2 
have been identified. These peptides have proven antimicrobial, antifungal and antiviral 
(including anti-HIV) activities. There were high concentrations of these salivary defensin 
peptides (2-350 mg/mL) in ten healthy subjects; this may have potentially important 
therapeutic applications such as the prevention and / or treatment of oral candidiasis and 
other infections. 
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